| الوصف: |
Generalized pustular psoriasis (GPP) is a rare, life-threatening disease characterized by widespread eruptions of sterile pustules. Spesolimab is a new monoclonal antibody targeting the IL36RN receptor, directed at the treatment and prevention of GPP flares. Given its recent approval, there are few studies evaluating the efficacy and safety of spesolimab in treating this condition. This systematic review, to our knowledge the first on the topic, aimed to assess spesolimab as an effective and safe treatment for GPP flares. Evaluated herein are the available studies on the topic, sourced from PubMed, Scopus, and Web of Science until October 20 th, 2023. Ten reports were reviewed, including randomized controlled trials and respective subanalyses, case series and case reports, encompassing one hundred and ninety GPP patients treated with spesolimab. These studies reported consistent improvement in Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score and GPPGA pustulation subscore after the administration of a single endovenous dose of 900 mg of spesolimab versus placebo. There was no connection shown between the presence of a IL36RN mutation and a more favorable response to spesolimab. Conclusively, no negative side effects warranted discontinuing treatment as most reported were mild, the most common being infections. In summary, the reviewed data demonstrates that spesolimab proves effective in rapidly treating and preventing flares, with a favorable safety profile, in patients suffering from generalized pustular psoriasis. |